Preclinical study demonstrates eradication of catheter-associated Acinetobacter baumannii biofilms by novel phages, highlighting their therapeutic potential against drug-resistant infections.
Bacteriophage-derived depolymerases provide promising scaffolds for the rational design of next-generation anti-biofilm peptides. We report two novel lytic Caudoviricetes phages φAB440 and φAB441, targeting multidrug-resistant hypermucoviscous Acinetobacter baumannii , encoding tail-associated depolymerases with pectate lyase domains and endolysins featuring glycoside hydrolase motifs. Depolymerases and endolysins demonstrated high binding affinity towards capsular polysaccharide K15 (−9.2 kcal/mol) and NAG-NAM tetramers (−7.86 kcal/mol). Synteny analysis revealed significant genome rearrangement and divergence in both phages, more strongly in φAB441. Phage φAB441’s rare codon bias enables efficient depolymerase expression with altered tRNA availability in biofilms. Phages φAB440 and φAB441 suppressed bacterial growth over 24 h at low MOIs (10⁻¹ and 10⁻³), without evidence of resistance development. Four-day-old biofilms formed on urinary catheters were completely eradicated at 10⁹-10 8 PFU/ml, with ~7.2–7.4 log₁₀ CFU reductions. Phage φAB441, when tested against A. baumannii infection in Caenorhabditis elegans , increased survival of nematodes to 75.97%, 73.97%, and 73.7% at MOIs 1000, 100, and 10, respectively. Our findings highlight the importance of structural validation and in silico analysis towards determining the therapeutic potential of phage lytic proteins.
No takes yet. Share an insight, caveat, or question.
Vashisth et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: